In an experiment conducted in japan, it has been proved that even one person can easily spread germs if he/she is infected.

The experiment was&nbsp;conducted by the public broadcasting organization NHK and health experts. It was setup similar to&nbsp;a buffet restaurant or on a cruise ship.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/kGQEuuv9R6E" width="560"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The experiment shows 10 people dining in a buffet. The participants, unknown of the one infected person, carry on to the buffet and settle down on the table, as per normal circumstances. However, at the end of the experiment,&nbsp;the participants are cast under black lights illuminating where the infection has spread.

<a href="https://www.wionews.com/world/who-putting-nations-at-risk-by-excluding-taiwan-from-knowledge-sharing-us-report-298412">Also read:&nbsp;WHO putting nations at risk by excluding Taiwan from knowledge sharing: US report</a>

A substance was used to signify the germs/infection. When the participants were subjected to black light, the substance could be&nbsp;seen on food, serving utensils and platters, and even on the faces of some of them.

"What the video demonstrated, is that it will spread to surfaces and to people very efficiently and I think it really highlights the need of what people have been saying about hand hygiene to stop the spread of disease," John Nicholls, a clinical professor in pathology at Hong Kong University explained to a media organization.

However, the experiment cannot be believed completely as majority focus of the group was on touching substances.

Another way of conducting this experiment that the experts have suggested is to let the infected person wash his/her hands for 5-10 seconds and then observe the spread of the infection.

This experiment has, however,&nbsp;proved how easily the virus can spread in public gatherings even if just one person is infected.

In an experiment conducted in japan, it has been proved that even one person can easily spread germs if he/she is infected. The experiment was conducted by the public broadcasting organization NHK and health experts.

In an experiment conducted in japan, it has been proved that even one person can easily spread germs if he/she is infected. The experiment was conducted by the public broadcasting organization NHK and health experts. It was setup similar to a buffet restaurant or on a cruise ship. × The experiment shows 10 people dining in a buffet. The participants, unknown of the one infected person, carry on to the buffet and settle down on the table, as per normal circumstances. However, at the end of the experiment, the participants are cast under black lights illuminating where the infection has spread. Also read: WHO putting nations at risk by excluding Taiwan from knowledge sharing: US report A substance was used to signify the germs/infection. When the participants were subjected to black light, the substance could be seen on food, serving utensils and platters, and even on the faces of some of them. "What the video demonstrated, is that it will spread to surfaces and to people very efficiently and I think it really highlights the need of what people have been saying about hand hygiene to stop the spread of disease," John Nicholls, a clinical professor in pathology at Hong Kong University explained to a media organization. However, the experiment cannot be believed completely as majority focus of the group was on touching substances. Another way of conducting this experiment that the experts have suggested is to let the infected person wash his/her hands for 5-10 seconds and then observe the spread of the infection. This experiment has, however, proved how easily the virus can spread in public gatherings even if just one person is infected.

Japanese experiment shows how quickly one person can spread coronavirus

China launched an <a href="http://www.wionews.com/world/watch-china-launches-two-beidou-navigation-satellites-178120">experimental satellite </a>on Saturday morning as part of its major new Hongyun Project, which seeks to establish a low-orbit broadband communication satellite system to improve internet connectivity.

A Long March-11 rocket carrying the satellite blasted off from the Jiuquan Satellite Launch Center in northwest China at 07:51 local time and has successfully entered its preset orbit.

The launch, which is the first satellite of the Hongyun Project to put into orbit, marks the substantial progress China has made in mapping out the low-orbit broadband communication satellite system, according to the China Aerospace Science and Industry Corporation (CASIC).

The Hongyun project was initiated by CASIC in September 2016 and aims to build a space-based communications network to provide broadband internet connectivity to users around the world, especially those in underserved regions.

"Using a common expression, we are moving the Internet currently on the ground into the sky. The first satellite of the Hongyun Project is China's first true low-orbit broadband communication satellite, which will greatly promote the development of aerospace sectors, particularly commercial aerospace," said Hou Xiufeng, a CASIC spokesman.

CASIC plans to launch another four experimental Hongyun satellites before the end of 2020 to form a small network for Hongyun's trial run, the spokesman added.

The corporation currently intends to place 156 Hongyun satellites on orbits about 1,000 kilometres above ground by around 2023, while the constellation is likely to be further expanded in response to market demands.

Xiang Kaiheng, Hongyun's chief designer at the CASIC Space Engineering Development company in Beijing, said the satellite mainly carries broadband service communication devices, which will jointly verify the low-orbit satellite broadband communication technology with the receiving stations on the ground.

"At present, many areas can't be covered by the ground network. We can't get through to phones when we are in the mountainous area. In the future, with the support of the constellation, we can access the internet anytime and anywhere, even at sea," said the engineer.

China launched an experimental satellite on Saturday morning as part of its major new Hongyun Project, which seeks to establish a low-orbit broadband communication satellite system to improve internet connectivity.

China launched an experimental satellite on Saturday morning as part of its major new Hongyun Project, which seeks to establish a low-orbit broadband communication satellite system to improve internet connectivity. A Long March-11 rocket carrying the satellite blasted off from the Jiuquan Satellite Launch Center in northwest China at 07:51 local time and has successfully entered its preset orbit. The launch, which is the first satellite of the Hongyun Project to put into orbit, marks the substantial progress China has made in mapping out the low-orbit broadband communication satellite system, according to the China Aerospace Science and Industry Corporation (CASIC). The Hongyun project was initiated by CASIC in September 2016 and aims to build a space-based communications network to provide broadband internet connectivity to users around the world, especially those in underserved regions. "Using a common expression, we are moving the Internet currently on the ground into the sky. The first satellite of the Hongyun Project is China's first true low-orbit broadband communication satellite, which will greatly promote the development of aerospace sectors, particularly commercial aerospace," said Hou Xiufeng, a CASIC spokesman. CASIC plans to launch another four experimental Hongyun satellites before the end of 2020 to form a small network for Hongyun's trial run, the spokesman added. The corporation currently intends to place 156 Hongyun satellites on orbits about 1,000 kilometres above ground by around 2023, while the constellation is likely to be further expanded in response to market demands. Xiang Kaiheng, Hongyun's chief designer at the CASIC Space Engineering Development company in Beijing, said the satellite mainly carries broadband service communication devices, which will jointly verify the low-orbit satellite broadband communication technology with the receiving stations on the ground. "At present, many areas can't be covered by the ground network. We can't get through to phones when we are in the mountainous area. In the future, with the support of the constellation, we can access the internet anytime and anywhere, even at sea," said the engineer.

China launches experimental satellite to boost internet connectivity

A trial drug has shown encouraging signs of there being an effective treatment for Alzheimer&#39;s disease. 
 
The drug, named&nbsp;aducanumab, is an antibody that showed &quot;almost complete clearance&quot; of sticky proteins that clot in the brain, a reason that is believed to cause Alzheimer&#39;s. The sticky proteins are known as&nbsp;Amyloids. 
 
Experts, however, moved quickly to downplay the significance of the experiment.&nbsp; 
 
Robert Howard, a professor of old age psychiatry at University College London, told AFP,&nbsp;&quot;Although potentially this is an exciting story, it is important to temper any excitement with considerable caution.&quot; 
 
Incidentally,&nbsp;aducanumab is not the first antibody to show positive signs in Phase I&nbsp;of the drug trial. The Phase III efficacy test is the crucial period for any experimental drug.&nbsp; 
 
&quot;It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer&#39;s disease,&quot; professor Howard said.&nbsp; 
 
Aducanumab, an antibody developed by biotech firm Biogen, was used on 165 people suffering from early-stage Alzheimer&#39;s for a year.&nbsp; 
 
The drug recorded&nbsp;some side-effects, including headaches. 
 
Nearly 44 million people have Alzheimer&#39;s disease or a related dementia across the world. 
 
In the US, Alzheimer&#39;s is the sixth-leading cause of death.&nbsp;&nbsp; 
 
According to World Health Organisation (WHO), around 7.7 million people are diagnosed with the disease every year.&nbsp; 
 
At the moment, there is no effective treatment for&nbsp;Alzheimer&#39;s disease, which leads to memory loss in old age. 
 
(WION with inputs from AFP)

The antibody showed 'almost complete clearance' of sticky proteins that clot in the brain, a reason that is believed to cause the disease

A trial drug has shown encouraging signs of there being an effective treatment for Alzheimer's disease. The drug, named aducanumab, is an antibody that showed "almost complete clearance" of sticky proteins that clot in the brain, a reason that is believed to cause Alzheimer's. The sticky proteins are known as Amyloids. Experts, however, moved quickly to downplay the significance of the experiment. Robert Howard, a professor of old age psychiatry at University College London, told AFP, "Although potentially this is an exciting story, it is important to temper any excitement with considerable caution." Incidentally, aducanumab is not the first antibody to show positive signs in Phase I of the drug trial. The Phase III efficacy test is the crucial period for any experimental drug. "It would be premature to conclude that this is likely to represent an effective treatment for Alzheimer's disease," professor Howard said. Aducanumab, an antibody developed by biotech firm Biogen, was used on 165 people suffering from early-stage Alzheimer's for a year. The drug recorded some side-effects, including headaches. Nearly 44 million people have Alzheimer's disease or a related dementia across the world. In the US, Alzheimer's is the sixth-leading cause of death. According to World Health Organisation (WHO), around 7.7 million people are diagnosed with the disease every year. At the moment, there is no effective treatment for Alzheimer's disease, which leads to memory loss in old age. (WION with inputs from AFP)

Trial drug kindles hopes of Alzheimer's treatment

Nestle, the world&#39;s biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants.

The Swiss group will pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow&rsquo;s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said on Tuesday.

Shares in the French biotech company rose 5 percent on the news.

The deal underscores Nestle&#39;s ambitions for its&nbsp;Health&nbsp;Science division, which it believes could eventually generate more than 10 billion Swiss francs ($10 billion) in annual sales.

It also complements the company&#39;s market-leading infant formula business and could help lift sales of products designed for babies with food intolerance.

Nestle has signed a series of similar deals with other small companies in its bid to create a new kind business that is midway between food and pharmaceuticals. The goal is to find new ways to treat, diagnose and prevent a range of diseases, from gastrointestinal problems to Alzheimer&#39;s.

CMPA affects up to 2 or 3 percent of infants and toddlers, according to the companies. Many others, however, have symptoms suggestive of the condition, creating a need for a simple diagnostic test.

Under the terms of the agreement, DBV will be eligible to receive up to 90 million euros in development, regulatory and commercial milestones - on top of the upfront payment - and will also collect royalties on eventual product sales.

&ldquo;This innovation can become the breakthrough diagnostic for CMPA,&quot; said Greg Behar, chief executive of Nestl?&nbsp;Health&nbsp;Science.

The new test will need to go through extensive clinical trials before it is cleared for sale and DBV expects it to be submitted for approval to regulators worldwide by 2021.

Behar&#39;s division, which employs around 3,000 people, is an expanding part of Nestle&#39;s operations.

Given ageing populations around the world and spiralling cases of lifestyle diseases, the Swiss group sees big opportunities in&nbsp;health&nbsp;- but the initiative also poses new challenges by taking it into the highly regulated medical field.

Strategically the shift towards&nbsp;health&nbsp;offers Nestle a hedge against slowing growth in packaged foods and may also offset crackdowns on unhealthy foods blamed for obesity and other lifestyle problems.

The milk allergy test dovetails with Nestle&#39;s presence in infant formula, where it had 22 percent of the market in 2015, according Euromonitor International. It already has a range of products called Althera, Alfare and Alfamino that are designed for infants allergic to cow&rsquo;s milk.

For DBV, the deal is a vindication of its Viaskin patch technology. The company also has a patch to treat peanut allergy in clinical trials, as well as an earlier-stage programme for egg allergy.

Nestle, the world's biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants

Nestle, the world's biggest food company, is stepping up its push into medicine with a global deal worth up to 100 million euros ($111 million) to develop and market an experimental milk allergy test for infants. The Swiss group will pay DBV Technologies 10 million euros upfront for rights to its skin patch test for cow’s milk protein allergy (CMPA), with the balance depending on successful development, the two companies said on Tuesday. Shares in the French biotech company rose 5 percent on the news. The deal underscores Nestle's ambitions for its Health Science division, which it believes could eventually generate more than 10 billion Swiss francs ($10 billion) in annual sales. It also complements the company's market-leading infant formula business and could help lift sales of products designed for babies with food intolerance. Nestle has signed a series of similar deals with other small companies in its bid to create a new kind business that is midway between food and pharmaceuticals. The goal is to find new ways to treat, diagnose and prevent a range of diseases, from gastrointestinal problems to Alzheimer's. CMPA affects up to 2 or 3 percent of infants and toddlers, according to the companies. Many others, however, have symptoms suggestive of the condition, creating a need for a simple diagnostic test. Under the terms of the agreement, DBV will be eligible to receive up to 90 million euros in development, regulatory and commercial milestones - on top of the upfront payment - and will also collect royalties on eventual product sales. “This innovation can become the breakthrough diagnostic for CMPA," said Greg Behar, chief executive of Nestl? Health Science. The new test will need to go through extensive clinical trials before it is cleared for sale and DBV expects it to be submitted for approval to regulators worldwide by 2021. Behar's division, which employs around 3,000 people, is an expanding part of Nestle's operations. Given ageing populations around the world and spiralling cases of lifestyle diseases, the Swiss group sees big opportunities in health - but the initiative also poses new challenges by taking it into the highly regulated medical field. Strategically the shift towards health offers Nestle a hedge against slowing growth in packaged foods and may also offset crackdowns on unhealthy foods blamed for obesity and other lifestyle problems. The milk allergy test dovetails with Nestle's presence in infant formula, where it had 22 percent of the market in 2015, according Euromonitor International. It already has a range of products called Althera, Alfare and Alfamino that are designed for infants allergic to cow’s milk. For DBV, the deal is a vindication of its Viaskin patch technology. The company also has a patch to treat peanut allergy in clinical trials, as well as an earlier-stage programme for egg allergy.

Nestle, on health kick, moves into milk allergy testing

experimental

Experimental, News on Experimental, stories on Experimental, articles on Experimental, Experimental stories at Wion, Experimental news, Experimental latest news